AZ, Daiichi ink co-marketing deal on Nexium

AstraZeneca (AZN.L) and Daiichi Sankyo (4568.T) said they have agreed to co-promote and supply the heartburn treatment Nexium in Japan in a deal that includes a $100 million up-front payment to AstraZeneca. Report

Suggested Articles

After a major label expansion in December, Amarin's Vascepa is preparing a major boom in sales with its marketing team nearly scaled up.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

Data on Roche's Polivy aren't yet enough to win support from England's cost watchdogs, who rejected the medicine based on long-term…